Search

Displaying results 5261 - 5270 of 7500 in total
  1. Drug

    Enlonstobart

    go.drugbank.com/drugs/DB21890
    Investigational

    [A274486] It targets the programmed cell death protein 1 (PD-1), is being developed by the CSPC Pharmaceutical Group for the treatment of advanced cervical cancer and other solid tumours.

  2. Drug

    Avena sativa flowering top

    go.drugbank.com/drugs/DB14253
    Approved

    It is not an approved drug.

  3. Drug

    Adafosbuvir

    go.drugbank.com/drugs/DB14906
    Investigational

    Adafosbuvir is under investigation in clinical trial NCT02894905 (A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of AL-335).

  4. Drug

    Bixalomer

    go.drugbank.com/drugs/DB15200
    Investigational

    Bixalomer is under investigation in clinical trial NCT01115985 (A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Atorvastatin in Healthy Volunteers).

  5. Drug

    MIV-701

    go.drugbank.com/drugs/DB05736
    Experimental

    MIV-701 is a selective, potent inhibitor of the protease Cathepsin K. It is developed for the treatment of osteoporosis.

  6. Drug

    Metyrosine

    go.drugbank.com/drugs/DB00765
    ApprovedInvestigational

    It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. (Martindale, The Extra Pharmacopoeia, 30th ed)

  7. Drug

    Ranirestat

    go.drugbank.com/drugs/DB05327
    Investigational

    It has been used in trials studying the treatment of Mild to Moderate Diabetic Sensorimotor Polyneuropathy.

  8. Drug

    NGX267

    go.drugbank.com/drugs/DB05152
    Investigational

    It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.

  9. Drug

    Lutropin alfa

    go.drugbank.com/drugs/DB00044
    ApprovedInvestigational

    In males, LH stimulates Leydig cell to produce testosterone.

  10. Drug

    Zosuquidar

    go.drugbank.com/drugs/DB06191
    Investigational

    It is now in "Phase 3" of clinical tests in the United States. Its action mechanism consists of the inhibition of P-glycoproteins; other drugs with this mechanism include tariquidar and laniquidar.